- Open
- 9.35
- High
- 9.40
- Low
- 9.30
- Close
- 9.32
- Change
- -0.05 (-0.53%)
- Volume
- 549,799
| 15 Oct 2026 | 07:00:08 | Issue of Equity, Director Dealing & Voting Rights |
| 9 Oct 2026 | 07:00:02 | Preliminary Results |
| 2 Oct 2026 | 07:00:03 | Notice of GM |
| 24 Sept 2026 | 07:00:06 | Scancell completes up to US$25m in debt financing |
| 24 Sept 2026 | 06:00:00 | Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development |
| 31 Oct 2024 | Annual Report and Accounts (to 2024-04-30) | |
| 6 Nov 2023 | Annual Report and Accounts (to 2023-04-30) | |
| 3 Nov 2022 | Annual Report and Accounts (to 2022-04-30) |
Scancell Holdings PLC develops cancer treatments using its ImmunoBody®, Moditope®, and AvidiMabTM technology platforms. The company focuses on creating therapies for various types of cancer and has multiple products in development. Its business model includes generating revenue through collaboration agreements and potential funding from investors.
| 15 Oct 2026 | 07:00:08 | Issue of Equity, Director Dealing & Voting Rights |
| 9 Oct 2026 | 07:00:02 | Preliminary Results |
| 2 Oct 2026 | 07:00:03 | Notice of GM |
| 24 Sept 2026 | 07:00:06 | Scancell completes up to US$25m in debt financing |
| 24 Sept 2026 | 06:00:00 | Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development |
| 31 Oct 2024 | Annual Report and Accounts (to 2024-04-30) | |
| 6 Nov 2023 | Annual Report and Accounts (to 2023-04-30) | |
| 3 Nov 2022 | Annual Report and Accounts (to 2022-04-30) |
Scancell Holdings PLC develops cancer treatments using its ImmunoBody®, Moditope®, and AvidiMabTM technology platforms. The company focuses on creating therapies for various types of cancer and has multiple products in development. Its business model includes generating revenue through collaboration agreements and potential funding from investors.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £313m | -0.1% | |
| £285m | -0.4% | |
SCLPScancell Holdings PLC | £113m | -0.0% |
| £38m | +0.3% | |
| £24m | -0.6% | |
| £11m | +0.0% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £313m | -0.1% | |
| £285m | -0.4% | |
SCLPScancell Holdings PLC | £113m | -0.0% |
| £38m | +0.3% | |
| £24m | -0.6% | |
| £11m | +0.0% |
